media – Page 49 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Humanwell Pharmaceuticals and JD.com hold talks on full-link cooperation in the pharmaceutical field

July 28th, the Industrial Development Department/Business Collaboration Department of China Merchants Group and China Merchants Innovation and Technology jointly organized Renfu PharmaceuticalA delegation visited JD.comAt the group headquarters, talks were held with JD Government and Enterprise, JD Health , and JD Logistics teams on deepening cooperation across the entire pharmaceutical chain. At the meeting, core business units of Renmin Pharmaceutical , including Yichang Renmin, Xinjiang Uyghur Medicine, Gedian Renmin, Renmin Puke, Yichang Three Gorges Pharmaceutical, and Wuhan Tianrun, focused on the core demands of e-commerce development and proposed cooperation directions. The JD team responded positively, stating that it will integrate on-site marketing resources, optimize operational docking, open data support, and provide assistance in logistics technology, channel management, and vertical platform construction (such as ethnic medicine halls and pet pharmacies). https://finance.eastmoney.com/a/202508033474553678.html
- Source: drugdu
- 77
- August 4, 2025
Hybio Pharmaceuticals and KuCoin have reached a strategic cooperation to explore the innovative drug RWA project

According to Hybio Pharmaceutical, on August 4, Hybio Pharmaceutical and digital asset platform KuCoin officially signed a letter of intent for strategic cooperation. The two parties intend to jointly explore and promote the first ” innovative drug” in mainland China in Hong Kong. This is a pilot project for tokenizing RWA (Real World Asset) with the future income rights of R&D as the underlying asset. According to the agreement, Hybio Pharmaceutical will use its technology accumulation and R&D pipeline in the field of GLP-1 peptide blockbuster drugs as the underlying asset, and KuCoin will leverage its blockchain The advantages in technology, RWA full-process solutions and global compliance resources provide the project with integrated support for on-chain mapping, asset tokenization, transaction matching, and profit distribution. https://finance.eastmoney.com/a/202508043475115419.html
- Source: drugdu
- 102
- August 4, 2025
China’s first! China’s CAR-T has a new addition

The NMPA official website shows that the Class 1 innovative biological product independently developed by Hengrun Dasheng, Renikiolunsai Injection (trade name: Hengkailai), has been approved for marketing in China . As China’s first fully independently developed CD19 CAR-T product for relapsed or refractory large B-cell lymphoma (r/r LBCL), its approval not only fills the gap in China’s CAR-T field, but also marks that China’s immune cell therapy technology has entered a new stage of independent control. The approval of Renykiolencil Injection was based on its excellent performance in clinical trials. In the Phase II HRAIN01-NHL01-II study, the drug enrolled 81 patients with relapsed/refractory non-Hodgkin’s lymphoma (R/R NHL) who had received at least two lines of therapy (including an anthracycline and a CD20-targeted drug) or autologous hematopoietic stem cell transplantation. Study results showed that Renykiolensay injection not only demonstrated a durable remission effect in patients with relapsed or refractory large B-cell ...
- Source: drugdu
- 114
- August 4, 2025
Profits soared 47 times as Hebo Pharmaceuticals continued its offensive

Recently, Hebo Pharmaceuticals released a positive earnings forecast: it expects profits of US$68 million (approximately HK$532 million) to US$74 million (approximately HK$579 million) in the first half of 2025. This figure represents a more than 47-fold increase from approximately US$1.4 million in the same period of 2024, and easily exceeds its projected full-year profit of US$2.778 million in 2024. Its profit growth mainly comes from BD cooperation income, of which the initial payment, milestone payment and option payment from AstraZeneca accounted for US$175 million. Since Harbour BioMed successfully turned a profit in 2023 through licensing revenue, the market has questioned the sustainability of this model. However, Harbour BioMed’s continued strong performance has proven that BD revenue can be converted into a stable and regular revenue stream, exploring a new path for innovative pharmaceutical companies to survive. Billions of BD orders ignited the performance explosion point As early as 2020, Hebo ...
- Source: drugdu
- 142
- August 4, 2025
【EXPERT Q&A】What are the main contents of compliance review for enterprises?

Drugdu.com expert’s response: Conducting compliance reviews is a critical step for enterprises to ensure their operations align with laws, regulations, industry standards, and internal rules and regulations. Its primary aim is to mitigate legal risks, safeguard corporate reputation, and promote sustainable development. The main areas covered by compliance reviews include laws and regulations, industry norms, internal systems, data protection and privacy, supply chain management, financial and tax compliance, labor and employment practices, environmental protection, anti-corruption and business ethics, and international trade compliance, among others. Here are the specifics: I. Compliance Review of Laws and Regulations National Laws and Regulations: Examine whether the enterprise’s business operations comply with national laws, administrative regulations, local ordinances, and other requirements, such as the Company Law, Contract Law, Labor Law, and Environmental Protection Law. Industry Regulatory Requirements: For specific industries (e.g., finance, healthcare, food, and pharmaceuticals), review compliance with special regulations set by industry regulatory bodies, such as capital ...
- Source: drugdu
- 152
- August 4, 2025
Several of the company’s products have obtained medical device registration certificates

On July 30, the company announced that it had recently received a medical device certificate issued by the Henan Provincial Drug Administration.The company has obtained registration certificates for a total IgE test kit, a β2-microglobulin test kit, a specific IgE antibody calibration kit, an aldosterone test kit, a dust mite allergen-specific IgE antibody test kit, and an artemisia allergen-specific IgE antibody test kit. These registration certificates enrich the company’s product portfolio and enhance its competitiveness, but will have a minimal impact on short-term operating performance. Post-launch sales of these products depend on the effectiveness of market promotion, and the impact on future operating income is currently unpredictable. Source：https://finance.eastmoney.com/a/202507303471485410.html
- Source: drugdu
- 131
- August 3, 2025
Wondfo Biologics’ subsidiary receives medical device registration certificate

On July 29, Wondfo Biotech(300482) announced that its wholly-owned subsidiary, Shenzhen Tianshen Medical EquipmentCo., Ltd. recently received medical device registration certificates issued by the State Food and Drug Administration and the Guangdong Provincial Food and Drug Administration . The approved products include multiple test kits, primarily used for the quantitative determination of relevant components in blood, and clinically used to assist in the diagnosis of various diseases. Specifically approved products include a tissue plasminogen activator-inhibitor 1 complex assay kit, a fibrinogen degradation product assay kit, and a plasmin-α2 plasmin inhibitor complex assay kit. These products, valid until 2030, cover the detection of thrombotic diseases and tumor markers, providing a richer testing menu for clinicians. The company stated that it will actively promote the sales of these products in the future, but it is currently unable to predict the specific impact of these products on the company’s performance. In the first ...
- Source: drugdu
- 115
- August 3, 2025
Fuyuan Pharmaceutical’s wholly-owned subsidiary, Bifonazole Solution, has been approved for registration

On July 30, Fuyuan PharmaceuticalDisclosure of the announcement regarding the receipt of the Drug Registration Certificate for Bifonazole Solution. Recently, the company’s wholly-owned subsidiary, Fuyuan Pharmaceutical Co., Ltd., received the Drug Registration Certificate (Certificate No.: 2025S02274) for Bifonazole Solution (Specification: 1% (10 ml: 0.1 g)) from the National Medical Products Administration, approving the production of the drug. This drug is used to treat the following fungal skin diseases: (1) Tinea pedis: Tinea pedis of the feet, body, and thighs. (2) Candidiasis: Interdigital erosions, intertrigo, and cutaneous candidiasis. (3) Vitiligo. Fuyuan Pharmaceutical received the application acceptance notice for its bifonazole solution on January 12, 2024, and recently received approval from the National Medical Products Administration (NMPA). According to relevant national policies and regulations, obtaining this Drug Registration Certificate is equivalent to passing the consistency evaluation, which will further enrich the company’s product line and help enhance the market competitiveness of its ...
- Source: drugdu
- 69
- August 3, 2025
Clinical Trial Application for LAE103 Approved by FDA

On July 31, Laekna Pharmaceuticals (02105) issued an announcement, announcing that its independently developed new drug LAE103 clinical trial (IND) application has been approved by the U.S. Food and Drug Administration (FDA). LAE103 is a monoclonal antibody targeting ActRIIB with the potential to treat sarcopenia and other muscle-related diseases. Source：https://finance.eastmoney.com/a/202507313472639341.html
- Source: drugdu
- 143
- August 3, 2025
FDA approves clinical trial application for CS231295 tablets

On July 31, Chipscreen Bio announced that its wholly-owned subsidiary, Chipscreen Biotech (USA), Inc., received FDA approval for a Phase I clinical trial of CS231295 for the treatment of advanced solid tumors. CS231295 is a brain-penetrating, selective inhibitor of Aurora B. Its superior blood-brain barrier penetration offers significant therapeutic advantages for primary and metastatic brain tumors. Currently, no other drug of this design has entered clinical trials globally. Brain tumors, due to the blood-brain barrier, make it difficult for most drugs to effectively enter the central nervous system, and have long been considered a “forbidden zone” in anti-tumor drug development. Chipscreen Biopharmaceuticals’ CS231295 has received FDA approval for clinical trials, demonstrating its differentiated innovation capabilities in brain tumor treatment. Source：https://www.yicai.com/news/102752034.html
- Source: drugdu
- 116
- August 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.